trifluoromethanesulfonic acid 5-chloro-1-cyclopropylmethyl-2-oxo-1,2-dihydropyridin-4-yl ester | 1128149-74-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: trifluoromethanesulfonic acid 5-chloro-1-cyclopropylmethyl-2-oxo-1,2-dihydropyridin-4-yl ester
• 英文别名: trifluoro-methanesulfonic acid 3-chloro-1-cyclopropylmethyl-2-oxo-1,2-dihydro-pyridin-4-yl ester；Trifluoromethanesulfonic acid 3-chloro-1-cyclopropylmethyl-2-oxo-1,2-dihydro-pyridin-4-yl ester；[3-chloro-1-(cyclopropylmethyl)-2-oxopyridin-4-yl] trifluoromethanesulfonate
• CAS: 1128149-74-5
• 化学式: C₁₀H₉ClF₃NO₄S
• 分子量: 331.7
• InChiKey: PDGPPTRTHPPRLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  trifluoromethanesulfonic acid 5-chloro-1-cyclopropylmethyl-2-oxo-1,2-dihydropyridin-4-yl ester 、 3-[2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-2,6-dimethyl-pyridine 在 四(三苯基膦)钯 碳酸氢钠 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 以13.5%的产率得到3-chloro-1-cyclopropylmethyl-4-[4-(2,6-dimethylpyridin-3-yloxy)-3-fluorophenyl]-1H-pyridin-2-one
  参考文献：
  名称：

  [EN] 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES
  [FR] 4-(ARYL-X-PHÉNYL)-1H-PYRIDINE-2-ONES 1,3-DISUBSTITUÉES

  摘要：

  本发明涉及新化合物，特别是根据式（I）的新吡啶酮衍生物，其中所有基团如申请和索赔中所定义。根据本发明的化合物是代谢型受体-亚型2（'mGluR2'）的阳性别构调节剂，对与谷氨酸功能障碍相关的神经系统和精神障碍以及涉及代谢型受体亚型mGluR2的疾病的治疗或预防是有用的。具体来说，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等疾病组中选择的中枢神经系统疾病。该发明还涉及制备这种化合物和组合物的药物组合物和方法，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病。

  公开号：

  WO2009033702A1
• 作为产物：
  描述：

  trifluoro-methanesulfonic acid 1-butyl-3-chloro-2-oxo-1,2-dihydropyridin-4-yl ester 、 3-Chloro-1-(cyclopropylmethyl)-4-hydroxypyridin-2(1H)-one 生成 trifluoromethanesulfonic acid 5-chloro-1-cyclopropylmethyl-2-oxo-1,2-dihydropyridin-4-yl ester
  参考文献：
  名称：

  1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones

  摘要：

  本发明涉及新型化合物，特别是公式（I）中定义的新型吡啶酮衍生物，其中所有基团均如本申请和权利要求所定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。特别是，这些疾病是选自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的一组。本发明还涉及制备这些化合物和组合物的制药组合物和过程，以及将这些化合物用于预防和治疗涉及mGluR2的这些疾病的用途。

  公开号：

  US08252937B2

文献信息

• [EN] INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] DÉRIVÉS D'INDOLE ET DE BENZOMORPHOLINE EN TANT QUE MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010043396A1

  公开（公告）日：2010-04-22

  The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新颖化合物，特别是根据式(I)的新型吲哚和苯并吗啡啉衍生物，其中所有基团如申请和索赔中所定义。根据本发明的化合物是代谢型受体-亚型2（"mGluR2"）的阳性变构调节剂，对于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体中mGluR2亚型的疾病是有用的。特别是，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫的中枢神经系统疾病。该发明还涉及制备这种化合物和组合物的药物组合物和过程，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病。
• INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Cid-Nunez Jose Maria

  公开号：US20110275624A1

  公开（公告）日：2011-11-10

  The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及一种新型化合物，特别是根据公式（I）中定义的所有基团的新型吲哚和苯并吗啡衍生物。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型2的疾病。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病中选择的。本发明还涉及制备这种化合物和组合物的制药组合物和制备过程，以及使用这种化合物预防和治疗涉及mGluR2的这些疾病。
• 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES
  申请人：DUVEY Guillaume Albert Jacques

  公开号：US20120309793A1

  公开（公告）日：2012-12-06

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新颖化合物，特别是公式（I）中定义的新型吡啶酮衍生物，其中所有基团均如申请和权利要求中所定义。本发明的化合物是代谢型受体-亚型2（“mGluR2”）的正变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体mGluR2亚型的疾病。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病组中选择的。本发明还涉及制备这样的化合物和组合物的制药组合物和过程，以及使用这些化合物预防和治疗涉及mGluR2的这些疾病。
• US8252937B2
  申请人：——

  公开号：US8252937B2

  公开（公告）日：2012-08-28
• US8748621B2
  申请人：——

  公开号：US8748621B2

  公开（公告）日：2014-06-10